Alphabet-backed start-up Isomorphic Labs has added another name to the roster of pharma companies tapping into its AI-based drug discovery engine. Johnson & Johnson's Janssen Biotech unit is the ...

Isomorphic Labs has raised a whopping $600 million to refine its artificial intelligence-powered drug discovery engine, advance its pipeline, and expand its headcount in its first external funding ...

Jan 20 (Reuters) - Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday.

Add Yahoo as a preferred source to see more of our stories on Google. Demis Hassabis speaks during the 56th annual World Economic Forum (WEF) meeting in Davos, Switzerland, January 20, 2026.

In 2024, Demis Hassabis won a Nobel Prize in chemistry for his work in predicting protein structures through his company, Isomorphic Labs. The lab, which broke off from Google's DeepMind in 2021, ...

Alphabet's AI drug development subsidiary Isomorphic Labs is aiming to initiate clinical trials for its AI-developed oncology drugs. In an interview with Fortune, Isomorphic Labs president Colin ...

Jan 20 (Reuters) - Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical ‌trials by the end of 2026, founder and CEO ‌Demis Hassabis said on ...

Jan 20 (Reuters) - Isomorphic Labs, ‌which uses artificial intelligence ‌for drug discovery, expects to have its first clinical trials by the ‍end of 2026, founder and CEO Demis Hassabis said ⁠on ...

Jan 20 : Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday. The ...

Read more: A сentury of сhemical warfare: why the global ban matters Swiss becomes first woman to head chemical weapons body Read more: Swiss becomes first woman to head chemical weapons body Bad ...